The Competition and Markets Authority (CMA) has published its final orders and, following strong BVA pushback, has substantially revised the wording and design of its client notice on medicines and prescriptions.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: